Poster # 75 Abstract # 9087


Phase II results of Ivonescimab (AK112/SMT112) a novel PD-1/VEGF bispecific in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK

1 Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China; 2. Hunan Cancer Hospital, Kunming, P. R. China; 4. The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China; 1. China; 3. Yunnan Cancer Hospital, Kunming, P. R. China; 4. The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China; 4. The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China; 4. The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China; 4. The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China; 4. The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China; 4. The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China; 4. The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China; 4. The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China; 4. The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China; 4. The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China; 4. The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China; 4. The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China; 4. The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China; 4. The First Affiliated Hospital of Anhui Medical University, Hefei, P. R. China; 5. The First Affi 5. Fujian Provincial Cancer Hospital, Fuzhou, P. R. China; 8. Affilliated Cancer Hospital and institute of Guangzhou Medical University, Guangzhou, P. R. China; 7. Respiratory Department of Internal Medicine, The Affiliated Cancer Hospital and institute of Guangzhou Medical University, P. R. China; 8. Affilliated Cancer Hospital and institute of Guangzhou Medical University, Guangzhou, P. R. China; 8. Affilliated Cancer Hospital and institute of Guangzhou Medical University, P. R. China; 8. Affilliated Cancer Hospital and institute of Guangzhou Medical University, P. R. China; 8. Affilliated Cancer Hospital and institute of Guangzhou Medical University, Guangzhou, P. R. China; 8. Affilliated Cancer Hospital and institute of Guangzhou Medical University, Guangzhou, P. R. China; 8. Affilliated Cancer Hospital and institute of Guangzhou Medical University, Guangzhou, P. R. China; 8. Affilliated Cancer Hospital and institute of Guangzhou Medical University, Guangzhou, P. R. China; 8. Affilliated Cancer Hospital and institute of Guangzhou Medical University, Guangzhou, P. R. China; 8. Affilliated Cancer Hospital and institute of Guangzhou Medical University, Guangzhou, P. R. China; 8. Affilliated Cancer Hospital and institute of Guangzhou Medical University, Guangzhou, P. R. China; 8. Affilliated Cancer Hospital and institute of Guangzhou Medical University, Guangzhou Medic 9. Hunan Provincial People's Hospital, Changsha, P. R. China; 10. Guizhou Provincial People's Hospital, Lanzhou, P. R. China; 12. Akeso Biopharma, Inc., Zhongshan, P. R. China; 13. Lanzhou University Second Hospital, Lanzhou Vicensity Second Hospital, Lanzhou, P. R. China; 12. Akeso Biopharma, Inc., Zhongshan, P. R. China; 14. Lanzhou University Second Hospital, Lanzhou Vicensity Second Hospital, Lanzhou Vicensity Second Hospital, Changshan, P. R. China; 14. Lanzhou Vicensity Second Hospital, Lanzhou Vicensity Second Hospital, Changshan, P. R. China; 14. Lanzhou Vicensity Second Hospital, C

BACKGROUND

Since the initial approval of bevacizumab (bev) with chemo in NSCLC, the subsequent focus of bev use in combination with PD1 therapy for first line metastatic disease has largely focused on non-squamous (non-sq) histology. Ivonescimab is a novel anti-PD-1/VEGF bispecific antibody. The bispecific approach to these targets has the potential to recalibrate the malignant immuno-architecture in favor of a more immune-responsive and anti-tumor microenvironment. In this trial, we aimed to assess the efficacy and safety of ivonescimab combined with chemotherapy for first line advanced or metastatic NSCLC in patients (pts) with squamous (Sq) or non-sq NSCLC.¹

Ivonescimab (AK112/SMT112): First-in-Class PD-1/VEGF Bispecific Antibody Brings two established mechanisms in oncology into ONE tetravalent molecule



Simultaneously engages both PD-1 & VEGF via 4 binding sites Designed to optimize the balance of anti-tumor activity and safety

Ivonesimab Mechanism Of Action

- Dual, simultaneous PD-1/VEGF blockade drives anti-tumor activity^{2,3} PD-1 blockade helps activate T cells⁴
- Antagonizing VEGF inhibits angiogenesis and leads to a more immuno-responsive tumor microenvironment (TME)⁵

Ivonescimab's structure enables higher avidity with >10-fold increase in PD-1 affinity in the presence of VEGF in vitro⁶


Potential to steer ivonescimab to the tumor versus healthy tissue

• High levels of PD-1 and VEGF expression in and around tumor tissue potentially allowing ivonescimab to simultaneously bind to both targets within the TME^{1,6,7}

Engineered Fc-null region could lead to reduced adverse events

 Modification of Fc-null region reduces FcgR binding leading to reduction in ADCC, ADCP, and CDC in vitro^{2.8} and no meaningful infusional cytokine release (IL-6 and TNF α) in patients²

Ivonescimab's T_{1/2} of 6-7 days provides sufficient blockade of both targets. A shorter $T_{1/2}$ could potentially lead to a favorable safety profile^{1,7}



METHODS

An open-label, multi-center phasell study evaluating the efficacy and safety of ivonescimab combined with chemotherapy in pts with advanced or metastatic NSCLC. Pts were enrolled into 3 cohorts based on prior therapy and presence of AGA. Data from pts with prior therapy for advanced or metastatic disease were presented in ASCO 2022 and here we report additional pts and longer follow-up data (see Table 4) from pts with NSCLC without AGA receiving first line therapy for advanced/metastatic disease. Pts were treated with 10 or 20 mg/kg ivonescimab once every 3wks combined with carboplatin and pemetrexed (non-sq) or carboplatin and paclitaxel (Sq). The primary endpoint was ORR per RECIST 1.1 by investigator (Figure 1).

Study Design¹

Cohort 1 1L without EGFR/ALK alterations

> Cohort 2 (non-sq) EGFR+ adv Progressed after EGFR-TKI

Cohort 3 Progressed after platinum-doublet and PD-1

Baseline Characteristics

As of data cut-off Feb 1, 2023, 135 pts were enrolled with advanced or metastatic NSCLC received ivonescimab plus chemotherapy including 63 with Sq and 72 with non-Sq. Median age was 61 yrs. 78% male, 3% and 97% pts had ECOG PS 0 and 1, respectively, and 20% pts had brain metastasis at baseline. See Table 1 for Baseline Characteristics.

Table 1. Baseline Ch

Age, median (ran

Male, n (%)

ECOG PS 1, n (%)

Smoking status, I Former or Curre Never

PD-L1 TPS, n (%):


Stage IV, n (%)

Distant metastatio Brain metastas Liver metastas Bone, n (%)

Central squamou Tumors with necr Invasion of large History of hemop

Ming Zhou⁸, Weidong Zhang⁹, Yu Zhang¹⁰, Yixin Wan¹¹, Weifeng Song¹², Michelle Xia¹²

METHODS



haracteristics	

	Squamous NSCLC (N=63)	Non-Squamous NSCLC (N=72)	Total (N=135)
nge), years	60 (40 - 76)	62 (38 - 72)	61 (38 - 76)
	52 (83)	53 (74)	105 (78)
)	61 (97)	70 (97)	131 (97)
n (%): rent	47 (75) 16 (25)	43 (60) 29 (40)	90 (67) 45 (33)
o: <1 % 1-49% ≥50%	24 (38) 24 (38) 14 (22)	38 (53) 17 (24) 15 (21)	62 (46) 41 (30) 29 (22)
	45 (71)	70 (97)	115 (85)
tic sites ≥3 sis, n (%) sis, n (%)	8 (13) 5 (8) 10 (16) 13 (21)	32 (44) 22 (31) 14 (19) 34 (47)	40 (30) 27 (20) 24 (18) 47 (35)
us NSCLC rosis/cavitation vessels otysis	38 (60) 12 (19) 9 (14) 13 (21)	n/a n/a n/a n/a	n/a n/a n/a n/a

SAFETY


Table 2. Ivonescimab Chemo Combination in 1L Advanced/Metastatic NSCLC Safety Results

Summary of Safety
Grade ≥3 TEAE
Grade ≥3 TRAE
TESAE
TRSAE
TEAE leading to AK112 discontinuati
TRAE leading to AK112 discontinuation
TEAE leading to death
TRAE leading to death

TEAE: Treatment-emergent adverse event TESAE: Treatment-emergent serious adverse event

The most common treatment-emergent adverse events (TEAEs) in SCC were anemia, neutrophil count decreased, and alopecia. In non-SCC, they were anemia, neutrophil count decreased, and constipation (details see figures above). Grade ≥3 TEAEs occurred in 60% and 56% of pts in Sq and non-Sq, respectively.

Ivonescimab Chemo Combination in 1L Advanced/Metastatic NSCLC TEAE >=20% (%)



• In Squamous NSCLC: all grade and grade ≥ 3 creatine increase were 8% and 0%,

all grade and grade \geq 3 blood pressure increased were 13% and 2%

• In Non-squamous NSCLC: all grade and grade ≥ 3 creatine increase were 19% and 0%, all grade and grade \geq 3 blood pressure increased were 8% and 0%

Table 3. Ivonescimab Chemo Combination in 1L Advanced/Metastatic NSCLC Adverse events of interest


Immune-related Adverse Events

		Total	(N=135)	SQ (N=63)		Non-SQ (N=72)	
Adverse Event in >1%	Any Grade (%)	(N=133) Grade ≥3 (%)	Adverse Event in >1%	Any Grade (%)	Grade ≥3 (%)	Any Grade (%)	Grade ≥3 (%)
Hypothyroidism	8 (5.9)	0 (0)	Epistaxis	13 (20.6)	0 (0)	25 (34.7)	1 (1.4)
Immune-mediated lung disease	6 (4.4)	3 (2.2)	Gingival bleeding	5	0	6	0
Rash	6 (4.4)	1 (0.7)		(7.9)	(0)	(8.3)	(0)
Pruritus	6 (4.4)	0 (0)	Hemoptysis	6 (9.5)	1 (1.6)	3 (4.2)	0 (0)
TSH increased	5 (3.7)	0 (0)	Hematochezia	1 (1.6)	0 (0)	1 (1.4)	0 (0)
Hyperthyroidism	4 (3.0)	0 (0)	Ductoinuurio	18	0	17	0
AST increased	2 (1.5)	1 (0.7) Proteinuria		(28.6)	(0.0)	(23.6)	(0)
ALT increased	2 (1.5)	1 (0.7)	Hypertension	9 (14.3)	3 (4.8)	5 (6.9)	2 (2.8)

Li Zhang¹, Wenfeng Fang¹, Yuanyuan Zhao¹, Yunpeng Yang¹, Ningning Zhou¹, Likun Chen¹, Yan Huang¹, Jianhua Chen², Li Zhuang³, Yingying Du⁴, Qitao Yu⁵, Wu Zhuang⁶, Yanqiu Zhao⁷,

	Squamous (N=63) n (%)		
	38 (60)	40 (56)	
	26 (41)	14 (19)	
	21 (33)	25 (35)	
	16 (25)	11 (15)	
ion	7 (11)	2 (3)	
ion	7 (11)	2 (3)	
	1(2)	7 (10)	
	0 (0)	3 (4)	

TRAE: Related Treatment-emergent adverse event TRSAE: Related treatment-emergent serious adverse event




■G1-2 ■G3-5

VEGF-related Adverse Events

Ivonescimab Chemo Combination in 1L Advanced/Metastatic NSCLC Median follow up 13.3 months

Percent Changes from Baseline in Target Lesions Sum of Diameters (N=129*)




*includes subjects with at least one post-baseline tumor assessment

ORR, DCR, and Median DOR


	Squamous N=60*	Non-squamous N=69*
ORR ⁺	67%	52%
[95% CI]	[53, 78]	[40, 64]
DCR ⁺	93%	93%
[95% CI]	[84, 98]	[84, 98]
Median DOR	15	18
[95% Cl], mo	[8, NE]	[11, NE]

*includes subjects with at least one post-baseline tumor assessment ⁺ ORR & DCR based on confirmed BOR


*NE=Non-estimable



Non-Squamous NSCLC (N=69*)



Ivonescimab Chemo Combination 1L Advanced/Metastatic NSCLC Progression Free Survival (N=135) - Median follow up 13.3 months



RESULTS



Ivonescimab Chemo Combination 1L Advanced/Metastatic NSCLC Overall Survival (N=135) - Median follow up 13.3 months

[─]┶<mark>╋┿┿┑╴╴┼╫┼╫┼┼╫╊╶┼┼┼╂</mark>╵┼╴╴┼╴┼╶┼╶┼╵╫╴┾┾┾┿ ╌╌╴ ╟╫╫╫╴┼╴╫╴┼┼┼┼╟╴╴┼ —— Squamous Cell Carcinoma Med OS, mo Est 9 mo OS – Non-Squamous Cell Carcinoma (95% CI) (95% CI) 93.2% Squamous NR (NE, NE) NSCLC (N=63) (82.8, 97.4) 81.5% NR (13,4, NE) NSCLC (N=72) (70.3, 88.8) 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Number at Risks (Event) Time (Month) 63(0) 63(0) 63(0) 63(0) 63(0) 62(1) 60(1) 56(2) 53(3) 51(4) 46(4) 40(4) 35(5) 23(5) 18(5) 14(5) 13(5) 12(5) 9(5) 6(5) 4(5) 0(5) 72(0) 72(0) 71(1) 69(3) 67(5) 67(5) 65(6) 63(8) 60(9) 55(13) 52(14) 48(15) 41(17) 36(18) 23(22) 17(22) 17(22) 16(22) 14(22) 11(22) 9(22) 3(22)

Median follow-up was 13.3 mo. Pts with Sq experienced a 67% ORR with median DOR 15 mo, 93% DCR, the 9-mo PFS and OS rate was 66% and 93%, respectively. Pts with non-Sq experienced a 52% ORR, median DOR 18 mo, 93% DCR, the 9-mo PFS rate and OS rate was 59% and 82%, respectively.

Table 4. Updated Ivonescimab in Combination with Chemo in ≥2L for Cohorts 2 & 3

	Cohort 2 (EGFR-TKI Relapsed NSCLC) N=19	Cohort 3* (PD-1/Platinum Relapsed NSCLC) N=20
Median Follow Up (range)	16.8 (3.8, 22.3)	16.8 (2.2, 20.3)
Confirmed ORR, %	68 (43, 87)	40 (19, 64)
DCR, % (95% CI)	95 (74, 99)	70 (46, 88)
DoR, mo (95% CI)	8.5	12.4
Median PFS, mo (95% CI)	8.5	7.1
Median OS, mo (95% CI)	NR (10.4, NE)	15.6 (8.4, NE)
Est 12 mo OS, % (95% CI)	74 (50, 88)	65 (40, 82)
Median duration of treatment (range), mo	8.5 (1.4, 23.0)	5.9 (1.4, 20.3)
Percent of patients on treatment at 12 months	6 (31.6)	7 (35.0)

In Sq. 4 (21%) and 15 (79%) pts received 1 and 2 prior line of therapy, respectively In non-Sq, 14 (70%), 5 (25%), and 1 (5%) pts received, 1, 2, and \geq 3 prior line of therapy, respectively.

*n=7 (35%) are squamous and n=13 (65%) are non-squamous pts

CONCLUSION

- Ivonescimab plus chemotherapy has shown promising anti-tumor activity in patients with advanced/metastatic NSCLC without EGFR and ALK genomic alterations.
- Ivonescimab can be administered safely in combination with platinum doublet chemotherapy to patients with Squamous and Non-Squamous histology.
- Ivonescimab is currently being evaluated in Phase III studies in NSCLC (NCT05184712).

Acknowledgements

References

- We are grateful to the patients and their care givers, to investigators and all site staff who participated in the ivonescimab-201 study.
- This study was sponsored by Akeso Biopharma, Inc.
- Editorial assistance was provided by Summit Therapeutics, Inc.

Please contact the author at zhangli6@mail.sysu.edu.cn for questions or comments

N=15 N=31

PFS, mo	Est 9 mo PFS
5% CI)	(95% CI)
11.0	65.7%
5, 16.8)	(51.6, 76.6)
12.3	58.8%
3, 19.3)	(46.4, 69.3)

1. Zhao Y., et al. JCO (June 01, 2022) 40, no. 16 suppl 9019 2. Manegold C., et al. JTO (2016) 12:2.194-207 3. Summit Therapeutics Inc. Data on File 14,15 4. Pardoll D. Nature Reviews Cancer (2012) vol. 12,4 :252-64 5. Tamura R., et al. Med Oncol (2020) 37:2, 10.1007 6. Zhong T., et al Journal for ImmunoTherapy of Cancer (2022) 10(2) 512 7. Zhou C., et al. JCO (June 01, 2022) 40, no. 16_suppl 9040 8. Huang Z., et al. Frontiers in immunology (27 Jun. 2022) vol. 13 924542.

